ID   NCC-PMP1-C1
AC   CVCL_B7BM
DR   cancercelllines; CVCL_B7BM
DR   Wikidata; Q112930163
RX   PubMed=35207746;
CC   Population: Japanese.
CC   Doubling time: ~147 hours (PubMed=35207746).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=35207746).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Right thigh; UBERON=UBERON_0000376.
ST   Source(s): PubMed=35207746
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 10,11
ST   D21S11: 30,32.2
ST   D5S818: 11
ST   D7S820: 9,11
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C3345; Pseudomyxoma peritonei
DI   ORDO; Orphanet_26790; Pseudomyxoma peritonei
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 7
//
RX   PubMed=35207746; DOI=10.3390/jpm12020258; PMCID=PMC8877412;
RA   Noguchi R., Yoshimatsu Y., Sin Y., Ono T., Tsuchiya R., Yoshida H.,
RA   Kiyono T., Yonemura Y., Kondo T.;
RT   "Establishment and characterization of NCC-PMP1-C1: a novel
RT   patient-derived cell line of metastatic pseudomyxoma peritonei.";
RL   J. Pers. Med. 12:258.1-258.15(2022).
//